glp 1 agonist cardioprotective Cardiovascular effects of Glucagon-like peptide (GLP-1) receptor agonists | Cardiovascular Diabetology Frontiers | GLP-1 Receptor Agonists:

Obesity is a complex disease, excessive fat accumulation caused by genetic, environmental and other factors, that has seen the most rapid growth in terms of ...

By Michael S

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.

We used version 2 of the Cochrane risk-of-bias tool for randomised trials to assess risk of bias for the primary outcome

Learn what the evidence shows about muscle symptoms with semaglutide, tirzepatide, and other GLP-1 medications, plus when to contact your doctor and how to protect muscle mass during treatment.